The groundbreaking success of Sildenafil undeniably reshaped the drug landscape, but investing in companies primarily reliant on off-patent versions presents a complex picture. While early returns were impressive, the end of patents and the rise of cheaper alternatives have diminished market share. Consequently, a thorough evaluation of ongoing rev